MoonLake Immunotherapeutics announces landmark Phase 2 : com

MoonLake Immunotherapeutics announces landmark Phase 2 results for Nanobody® sonelokimab in active psoriatic arthritis First placebo-controlled...

Related Keywords

Switzerland , Moonlake Immunotherapeutics , Ashley Tapp , Matthias Bodenstedt , Mary Jane Elliott , Namrata Taak , Patricia Sousa , Kristian Reich , Josephf Merola , Nasdaq , American College Of Rheumatology , Ut Southwestern Medical Center , Exchange Commission , Health Assessment Questionnaire , American College , Jorge Santos , Chief Executive Officer , Chief Scientific Officer , Distinguished Chair , Medical Center , Monday November , Psoriasis Area , Severity Index , Health Assessment Questionnaire Disability Index , Leeds Enthesitis Index , Patients Assessment , Hidradenitis Suppurativa Clinical Response , Global Assessment Score , Securities Litigation Reform Act , Annual Report , Jane Elliott , Nasdaq Mltx , Moonlake Immunotherapeutics Ag , Anobody 174 Sonelokimab , Jorge Santos Da Silva , Psoriatic Arthritis ,